With a new four-year, $1.3 million grant from the U.S. Department of Veterans Affairs, researchers at Case Western Reserve University are investigating a new approach to treat Acute Myeloid Leukemia ...
A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...
Secondary acute myeloid leukemia (AML) is a blood cancer that arises from other blood disorders or previous cancer treatment. Those with secondary AML tend to have a less favorable outlook than those ...
Acute myeloid leukemia (AML) is a type of blood and bone marrow cancer. AML can affect people of any age, but it is most common in adults. AML occurs when bone marrow produces abnormal blood cells, ...
Acute myeloid leukemia driven by tandem duplications within the UBTF gene (UBTF-TD AML) is a high-risk pediatric cancer in urgent need of novel therapeutic options. To better understand this disease ...
Relapsed acute myeloid leukemia (AML) is when cancer returns after a period of remission. Refractory AML means cancer has not responded to multiple rounds of treatment. Both can affect your treatment ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results